Hutchison China Meditech Limited Total Voting Rights (4379A)
September 30 2020 - 1:00AM
UK Regulatory
TIDMHCM
RNS Number : 4379A
Hutchison China Meditech Limited
30 September 2020
Total Voting Rights
London: Wednesday, September 30, 2020: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market
that as at September 30, 2020, the issued share capital of Chi-Med
consisted of 710,785,545 ordinary shares of US$0.10 each, with each
share carrying one right to vote and with no shares held in
treasury.
The above figure of 710,785,545 may be used by shareholders as
the denominator for the calculations by which they could determine
if they are required to notify their interest in, or a change to
their interest in, Chi-Med under the Financial Conduct Authority's
Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 710,785,545 ordinary shares
would be equivalent to 710,785,545 CREST depositary interests (each
equating to one ordinary share) which are traded on AIM or, if the
CREST depositary interests were converted in their entirety,
equivalent to 142,157,109 American depositary shares (each equating
to five ordinary shares) which are traded on Nasdaq.
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage,
biopharmaceutical company committed, over the past twenty years, to
the discovery and global development of targeted therapies and
immunotherapies for the treatment of cancer and immunological
diseases. It has a portfolio of nine cancer drug candidates
currently in clinical studies around the world and extensive
commercial infrastructure in its home market of China. For more
information, please visit: www.chi-med.com .
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97
83 6894 (Mobile), y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREAPNNASAEEEA
(END) Dow Jones Newswires
September 30, 2020 02:00 ET (06:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024